Products for Research Use Only
RegisterLogin

Cetrelimab

CAT: 0804-HY-P99499-01Size: 1 mgDry Ice: YesHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-P99499-01Size:1 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Cetrelimab (JNJ 63723283; JNJ 3283) is a human IgG4κ mAb targeting PD-1. Cetrelimab binds PD-1 (Kd=1.72 nM, HEK293) to block the interaction of PD-1 with PD-L1 and PD-L2 (IC50s=111.7 ng/mL and 138.6 ng/mL, respectively) . Cetrelimab stimulates peripheral T cells, increases IFN-γ, IL-2, TNF-α level and inhibits tumor growth in vivo[1].
CAS Number
2050478-92-5
Product Name Alternative
JNJ 63723283; JNJ 3283
UNSPSC
12352203
Target
Interleukin Related; PD-1/PD-L1; TNF Receptor
Type
Inhibitory Antibodies
Related Pathways
Apoptosis; Immunology/Inflammation
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/cetrelimab.html
Purity
99.0
Solubility
10 mM in DMSO
Smiles
[Cetrelimab]
Molecular Weight
(144.76 kDa)
References & Citations
[1]DeAngelis N, et al. Discovery and pharmacological characterization of cetrelimab (JNJ-63723283), an anti-programmed cell death protein-1 (PD-1) antibody, in human cancer models. Cancer Chemother Pharmacol. 2022 Apr;89 (4) :515-527.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Scientific Category
Inhibitory Antibodies
Clinical Information
Phase 3

Alternative Products

CatalogName
T76945-01Cetrelimab
GTR18337825-01Cetrelimab Antibody
DHH02204Research Grade Cetrelimab
E55K0555Cetrelimab ELISA Kit
KBI1229KRIBIOLISA™ Cetrelimab ELISA
E55B0453Cetrelimab (Reference antibody)
ABS-320-1mgCetrelimab Biosimilar, Research Grade
ICH5434-5mgCetrelimab Biosimilar - Research Grade
591747Cetrelimab (PDCD1, PD1, CD279)
A138343Cetrelimab Biosimilar (Monoclonal, IgG4)

Popular Products